Gamebird
Well-Known Member
Should I also assume then that, while there is no other prazinquantal product available, its more profitable for BOVA to just continue under this system, rather than go down the route of paying to licence their product?
I think you're being a little cynical about their morivations. BOVA aren't a drug company, they're a compounder/specials producer. So they won't be licencing it because that's just not something that they do. They produce formulations of unlicensed generic drugs that otherwise would be completely unobtainable. For example they produce the omeprazole injection for use for EGUS, ertugliflozin for EMS and various niche antibiotics specifically for things like Rhodococcus in foals. Most of these things are absolutely invaluable, but would be completely uneconomic to license. So they are produced as 'specials'.